11 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $570000 | -$26M | 0.0% | -5219.1% | -$33M | $0 | $24M |
| 2024 | $501000 | -$40M | 0.0% | -8710.0% | -$34M | $0 | $20M |
| 2023 | $424000 | -$28M | 0.0% | -6900.5% | -$25M | $0 | $31M |
| 2022 | $477000 | -$23M | 0.0% | -7189.7% | — | $0 | $31M |
| 2021 | $931000 | -$73M | -259.6% | -4179.5% | — | $0 | $42M |
| 2020 | $21M | -$256M | 93.4% | -1203.0% | — | $33M | $58M |
| 2019 | $443000 | -$95M | 100.0% | -21641.8% | — | $33M | $44M |
| 2018 | $4M | -$74M | 100.0% | -2083.2% | — | — | $28M |
| 2017 | — | -$29M | — | — | — | — | $10M |
| 2016 | — | -$14M | — | — | — | — | $4M |
| 2015 | — | -$5M | — | — | — | — | $44M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $86000 | -$4M | 0.0% | -4437.2% | — | $0 | $25M |
| Jun '25 | $69000 | -$6M | 0.0% | -10930.4% | — | $0 | $22M |
| Mar '25 | $202000 | -$9M | 0.0% | -4553.0% | — | $0 | $28M |
| Dec '24 | $84000 | -$12M | 0.0% | -15202.4% | — | $0 | $20M |
| Sep '24 | $121000 | -$12M | 0.0% | -10819.0% | — | $0 | $16M |
| Jun '24 | $198000 | -$9M | 0.0% | -5250.5% | — | $0 | $30M |
| Mar '24 | $98000 | -$6M | 0.0% | -7530.6% | — | $0 | $19M |
| Dec '23 | $76000 | -$6M | 0.0% | -8989.5% | — | $0 | $31M |
| Sep '23 | $114000 | -$7M | 0.0% | -5468.4% | — | $0 | $15M |
| Jun '23 | $135000 | -$10M | 0.0% | -7643.0% | — | $0 | $21M |
| Mar '23 | $99000 | -$6M | 0.0% | -5934.3% | — | $0 | $30M |
| Dec '22 | $6000 | -$10M | 0.0% | -133066.7% | — | $0 | $31M |
| Sep '22 | $167000 | -$9M | 0.0% | -5588.6% | — | $0 | $36M |
| Jun '22 | $126000 | -$8M | 0.0% | -6577.0% | — | $0 | $43M |
| Mar '22 | $178000 | $5M | 0.0% | -4882.6% | — | $0 | $50M |
| Dec '21 | $273000 | -$12M | -230.8% | -3240.3% | — | $0 | $42M |
| Sep '21 | $133000 | -$21M | -688.7% | -8095.5% | — | $0 | $52M |
| Jun '21 | $295000 | -$20M | -169.5% | -3234.6% | — | $33M | $103M |
| Mar '21 | $230000 | -$21M | -161.3% | -4242.2% | — | $35M | $119M |
| Dec '20 | $4M | -$23M | 87.5% | -513.0% | — | $33M | $58M |
How the market has priced VYNE against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, VYNE Therapeutics Inc.'s revenue has declined 51.4% per year. These are computed facts, not advice.
As of FY2025, VYNE Therapeutics Inc. reported $0 of total debt against $24M of cash.
In FY2025, gross margin was —, operating margin -5219.1%, and net margin -4646.1%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.